The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000575336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/04/2026
Date registered
Help: Date registered
7/05/2026
Date last updated
Help: Date last updated
7/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Trial of Electronic Patient Reported Outcome Measures (ePROMs) for the collection of primary endpoints in a trial of lignocaine for the prevention of post-operative pain in breast cancer surgery.
Scientific title
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial; Electronic Patient Reported Outcome Measures (ePROMs) Sub-study - validating the use of electronic follow up for the collection of primary endpoint.
Additional trial identifiers [1] 316948 0
Nil known
Universal Trial Number (UTN)
U1111-1338-4743
Trial acronym
LOLIPOP ePROMs Sub-Study
Related trial records
NCT05072314 LOLIPOP Trial - Main study of which this is a sub-study

Health condition
Health condition(s) studied:
Breast Cancer 341385 0
Condition category
Condition code
Cancer 337454 337454 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study aims to provide data on the reliability and acceptability of using electronically captured patient reported outcome measures (ePROMs) for the collection of primary endpoint data within the first large scale, multicentre Australian and New Zealand College of Anaesthesia (ANZCA) Clinical Trials Network (CTN) clinical trial using software provided by Research Path Pty Ltd.

All participants who have consented to participate in the LOLIPOP trial (Australia only), from the commencement of ePROMS substudy and application launch, will be approached for inclusion in the substudy. This substudy aims to validate the collection of patient reported chronic post-surgical pain 12 months following surgery for a primary breast cancer diagnosis via an electronic survey, as opposed to follow up phone call by a research coordinator.

For the purposes of the LOLIPOP trial, the primary endpoint is defined as:
The incidence of moderate or severe Chronic Post Surgical Pain (CPSP) at 1 year after surgery, as reported by the patient at
follow-up review. To meet the criteria for moderate or severe CPSP at 1 year, the reported pain:
a. Must be reported to be completely or partly caused by the breast surgery undertaken 1
year ago
b. Must have been present for at least 3 months
c. Must be reported as of “worst” intensity =4 out of 10 in the last week on the modified
Brief Pain Inventory Short Form (mBPI-SF).
d. Be in the area of the breast surgery performed 1 year ago or in one of the following
related areas: axilla, ipsilateral side of chest wall or ipsilateral upper arm.
e. Must not be clearly and exclusively attributable to another cause such as radiation therapy at or near the pain location, repeat surgery at or near the pain location, musculoskeletal injury at or near the pain location, infection at or near the pain location or recurrence of cancer at or near the pain location.

The ePROMs intervention will involve an automated email and/or SMS prompt being sent to the participant requesting the completion of the primary pain endpoint survey data via an online electronic survey. This will be triggered to send in line with the completion guidelines in the Case Report Form at the 12-month anniversary of the date of the index surgery. Weekly reminders for incomplete data will then be sent on weeks 1, 2, 3 and a final reminder sent 4 weeks following the 1-year anniversary of the index surgery. It is anticipated that the survey will take no more than 5 minutes to complete. Given the duplication of data for substudy participants, the ePROMs survey is an abridged version of the full 12 month follow up survey delivered by coordinator, designed only to validate the primary endpoint of the trial.

Following this final reminder, if the data remains unanswered, the participant will be marked as lost to follow up for the purposes of the sub-analysis of ePROMs data. All participants will also receive a research coordinator phone follow up for the 'standard' collection of primary outcome data. Additional questions will be asked as part of this follow up process for those additionally
enrolled in the substudy: around the ease of completion of ePROMs, any problems experienced by the participant in doing so, and the patient’s preferred method of follow-up for future research.
Intervention code [1] 333672 0
Other interventions
Description of the comparator or control
Incidence of moderate or severe CPSP at 1 year after surgery reported by the patient at phone follow-up review with research coordinator at 12 months post-surgery.
Control group
Active

Outcomes
Primary outcome [1] 344966 0
Reliability of electronic capture of PROMs primary outcome data
Timepoint [1] 344966 0
12 months post surgery
Primary outcome [2] 344967 0
Endpoint timing compliance of ePROMs survey completion
Timepoint [2] 344967 0
Endpoint timing compliance of phone survey completion at 12 months post surgery.
Primary outcome [3] 344968 0
Percentage of participants completing phone survey data within prescribed trial data point timeframe
Timepoint [3] 344968 0
12 months post surgery
Secondary outcome [1] 459952 0
Composite descriptive summary of overall function of ePROMs
Timepoint [1] 459952 0
12 months post surgery
Secondary outcome [2] 460976 0
Qualitative analysis of barriers to ePROMs completion
Timepoint [2] 460976 0
12 months post surgery

Eligibility
Key inclusion criteria
All participants who have consented to participate in the LOLIPOP trial (Australia only), from the commencement of ePROMS substudy and application launch, will be approached for inclusion in the substudy as an opt-in component.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Unable or unwilling to consent to participation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 321542 0
Hospital
Name [1] 321542 0
Metro South Hospital and Health Service
Country [1] 321542 0
Australia
Funding source category [2] 321701 0
Other
Name [2] 321701 0
Research Path Pty Ltd
Country [2] 321701 0
Australia
Funding source category [3] 321702 0
University
Name [3] 321702 0
Monash University
Country [3] 321702 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 324532 0
Other
Name [1] 324532 0
Research Path Pty Ltd
Address [1] 324532 0
Country [1] 324532 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320077 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320077 0
Ethics committee country [1] 320077 0
Australia
Date submitted for ethics approval [1] 320077 0
17/07/2023
Approval date [1] 320077 0
21/08/2023
Ethics approval number [1] 320077 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149358 0
Mrs Allison Kearney
Address 149358 0
Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, QLD, 4102
Country 149358 0
Australia
Phone 149358 0
+61 409286166
Fax 149358 0
Email 149358 0
Contact person for public queries
Name 149359 0
Allison Kearney
Address 149359 0
Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, QLD, 4102
Country 149359 0
Australia
Phone 149359 0
+61 409286166
Fax 149359 0
Email 149359 0
Contact person for scientific queries
Name 149360 0
Allison Kearney
Address 149360 0
Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, QLD, 4102
Country 149360 0
Australia
Phone 149360 0
+61 409286166
Fax 149360 0
Email 149360 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected],au

• [email protected],au

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    600-21 Amendment approval certificate 21-08-2023.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.